RxDoctor Payments Data

Waldo Acebo, MD

Family Medicine · Doral, FLNPI 1063451433

Payments from drug & device makers

$8,005in general payments, 2019–2025

Across 372 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Galderma Laboratories, L.p.$717
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$699
  • Amgen$595
  • Boehringer Ingelheim$591
  • Kowa Pharmaceuticals America, Inc.$554
  • plus $4K from 21 others

What the payments were for

  • Food & beverage$7,95399%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,005 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$29,265
Medicare patients
48
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$23,702
EliquisApixaban16$11,142
FarxigaDapagliflozin Propanediol12$6,876
Wixela InhubFluticasone Propion/Salmeterol19$1,865
Celecoxib37$1,704
Testosterone Cypionate28$1,265
Rosuvastatin Calcium47$982
ProgesteroneProgesterone, Micronized36$771
Telmisartan15$578
Clobetasol Propionate11$370
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$258
Metoprolol Succinate19$211
Atorvastatin Calcium25$201
Metformin Hcl21$181
Losartan Potassium26$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$537$23,70219 claims
PfizerEliquis$357$11,14216 claims
AstraZenecaFarxiga$265$6,87612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Doral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →